Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00995137 · ClinicalTrials.gov registry record · Phase 1

Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

A Phase 1 study, sponsored by St. Jude Children's Research Hospital.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target

NCT00995137: Completed Phase 1 study, sponsored by St. Jude Children's Research Hospital.

NCT00995137 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00995137, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target

Study Summary

This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).

Interventions

  • BIOLOGICAL NK Cell Infusion

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2009-10
Est. Completion 2014-05
Phase Phase 1

What the finished NCT00995137 record still lists

NCT00995137 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 1 intervention - of which NK Cell Infusion is the first listed.

NCT00995137 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00995137 about?

NCT00995137 is a clinical study titled "Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia". This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).

What is the current status of trial NCT00995137?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-10. Estimated completion is 2014-05.

What interventions are being tested in trial NCT00995137?

The interventions under investigation include: NK Cell Infusion (BIOLOGICAL).

Who is sponsoring clinical trial NCT00995137?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00995137's enrollment target sits among peer trials

14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00995137, the US trial registry maintained by the National Library of Medicine. NCT00995137 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.